|
1
|
Castleman B, Iverson L and Menendez VP:
Localized mediastinal lymphnode hyperplasia resembling thymoma.
Cancer. 9:822–830. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fajgenbaum DC, Uldrick TS, Bagg A, Frank
D, Wu D, Srkalovic G, Simpson D, Liu AY, Menke D, Chandrakasan S,
et al: International, evidence-based consensus diagnostic criteria
for HHV-8-negative/idiopathic multicentric Castleman disease.
Blood. 129:1646–1657. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartoli E, Massarelli G, Soggia G and
Tanda F: Multicentric giant lymph node hyperplasia. A hyperimmune
syndrome with a rapidly progressive course. Am J Clin Pathol.
73:423–426. 1980. View Article : Google Scholar
|
|
4
|
Gaba AR, Stein RS, Sweet DL and Variakojis
D: Multicentric giant lymph node hyperplasia. Am J Clin Pathol.
69:86–90. 1978. View Article : Google Scholar
|
|
5
|
Frizzera G, Banks PM, Massarelli G and
Rosai J: A systemic lymphoproliferative disorder with morphologic
features of Castleman's disease. Pathological findings in 15
patients. Am J Surg Pathol. 7:211–231. 1983. View Article : Google Scholar
|
|
6
|
Bonekamp D, Horton KM, Hruban RH and
Fishman EK: Castleman disease: The great mimic. Radiographics.
31:1793–1807. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Keller AR, Hochholzer L and Castleman B:
Hyaline-vascular and plasma-cell types of giant lymph node
hyperplasia of the mediastinum and other locations. Cancer.
29:670–683. 1972. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Deshmukh M, Bal M, Deshpande P and
Jambhekar NA: Synchronous squamous cell carcinoma of tongue and
unicentric cervical Castleman's disease clinically mimicking a
stage IV disease: A rare association or coincidence? Head Neck
Pathol. 5:180–183. 2011. View Article : Google Scholar
|
|
9
|
Pereira TC, Landreneau R, Nathan G and
Sturgis CD: Pathologic quiz case. Large posterior mediastinal mass
in a young woman. Pathologic diagnosis: Localized
hyaline-vascular-type Castleman disease (angiofollicular lymphoid
hyperplasia). Arch Pathol Lab Med. 125:964–967. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nishimoto N, Kanakura Y, Aozasa K, Johkoh
T, Nakamura M, Nakano S, Nakano N, Ikeda Y, Sasaki T, Nishioka K,
et al: Humanized anti-interleukin-6 receptor antibody treatment of
multicentric Castleman disease. Blood. 106:2627–2632. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
van Rhee F, Wong RS, Munshi N, Rossi JF,
Ke XY, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, et al:
Siltuximab for multicentric Castleman's disease: A randomised,
double-blind, placebo-controlled trial. Lancet Oncol. 15:966–974.
2014. View Article : Google Scholar
|
|
12
|
Nishimoto N, Sasai M, Shima Y, Nakagawa M,
Matsumoto T, Shirai T, Kishimoto T and Yoshizaki K: Improvement in
Castleman's disease by humanized anti-interleukin-6 receptor
antibody therapy. Blood. 95:56–61. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dispenzieri A, Armitage JO, Loe MJ, Geyer
SM, Allred J, Camoriano JK, Menke DM, Weisenburger DD, Ristow K,
Dogan A and Habermann TM: The clinical spectrum of Castleman's
disease. Am J Hematol. 87:997–1002. 2012. View Article : Google Scholar
|
|
14
|
Fujimoto S, Sakai T, Kawabata H, Kurose N,
Yamada S, Takai K, Aoki S, Kuroda J, Ide M, Setoguchi K, et al: Is
TAFRO syndrome a subtype of idiopathic multicentric Castleman
disease? Am J Hematol. 94:975–983. 2019. View Article : Google Scholar
|
|
15
|
Carbone A, Borok M, Damania B, Gloghini A,
Polizzotto MN, Jayanthan RK, Fajgenbaum DC and Bower M: Castleman
disease. Nat Rev Dis Primers. 7:842021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Matsumura N, Shiiki H, Saito N, Uramoto H,
Hanatani M, Nonaka H and Nakamura S: Interleukin-6-producing thymic
squamous cell carcinoma associated with Castleman's disease and
nephrotic syndrome. Intern Med. 41:871–874. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Riedel F, Zaiss I, Herzog D, Götte K, Naim
R and Hörmann K: Serum levels of interleukin-6 in patients with
primary head and neck squamous cell carcinoma. Anticancer Res.
25:2761–2765. 2005.PubMed/NCBI
|
